Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "MPD, MDS and Other Blood Disorders" returned 19 results:


Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients with Relapsed AL Amyloidosis
Principal Investigator(s): Keren Osman

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission. (CC-486-AML-001)
Principal Investigator(s): Lewis Silverman

A Phase 2 Pilot Trial of Ruxolitinib combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET) and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia
Principal Investigator(s): John Mascarenhas

Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia
Principal Investigator(s): Ronald Hoffman

A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients
Principal Investigator(s): Luis M. Isola

Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) with Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis – A phase II study
Principal Investigator(s): John O. Mascarenhas

A Phase II Controlled Trial of a Single ProHema-CB unit (Ex Vivo CXCR4-Upregulated CD34+ Hematopoietic Progenitor Cells, Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative Conditioning For Patients Age 15-55 Years With Hematologic Malignancies
Principal Investigator(s): Luis M. Isola

Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients with Myelodysplastic Syndrome with Excess Blasts Progressing On or After Azacitidine or Decitabine
Principal Investigator(s): Lewis Silverman

Filgrastim-Mobilized Blood Stem Cells for Transplantation
Principal Investigator(s): Luis M. Isola

An Open-Label, Multiple Simon 2-Stage Study of INCB039110 Administered Orally to Subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera-Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia-Myelofibrosis (PET-MF)
Principal Investigator(s): John O. Mascarenhas

MPD-RC 111: Single Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High Risk PV or High Risk ET who are Either Hydroxurea Resistent or Intolerant or Have Had Abdominal Vein Thrombosis
Principal Investigator(s): Ronald Hoffman

Combination Therapy of Ruxolitinib and Decitabine in patients with Myeloproliferative Neoplasms in Accelerated and Blast Phase Disease
Principal Investigator(s): John Mascarenhas

A Phase 3, Multicenter, Randomized, Double- Blind Study To Compare The Efficacy And Safety Of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In Subjects With Red Blood Cell Transfusion-Dependent Anemia And Thrombocytopenia Due To IPSS Lower-Risk Myelodysplastic Syndromes
Principal Investigator(s): Lewis Silverman

A Phase 2, Open-Label, Prospective Study of PRM-151 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), or Post-Essential Thrombocythemia MF (post-ET MF)
Principal Investigator(s): John Mascarenhas

A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
Principal Investigator(s): Luis M. Isola

Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib with Azacitidine in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
Principal Investigator(s): Shyamala Navada

Phase I/II Study of Combination oral JAK2 tyrosine kinase inhibitor (JAK2-TKI) and Histone Deacetylase Inhibitor (HDACI) therapy in patients with Myelofibrosis
Principal Investigator(s): John O. Mascarenhas

A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-1, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System
Principal Investigator(s): Lewis Silverman

A Phase 2, Multi-Center, Open Label, Randomized, Parallel-Group Study of A Lenalidomide (Revlimid) Regimen or A Sequential Azacitidine (Vidaza) plus Lenalidomide (Revlimid) Regimen versus Conventional Care for Therapy of Subjects 65 Years or Older with Newly Diagnosed Acute Myeloid Leukemia
Principal Investigator(s): Lewis R. Silverman